Skip to main content
PMC home page
Nature Portfolio logoLink to Nature Portfolio
. 2023 Oct 10;30(1):303. doi: 10.1038/s41591-023-02627-7

Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Jamie E Chaft 1,2,#, Filiz Oezkan 3,4,5,6,#, Mark G Kris 1,2, Paul A Bunn 7, Ignacio I Wistuba 8, David J Kwiatkowski 9,10, Dwight H Owen 3,11, Yan Tang 10, Bruce E Johnson 9,10, Jay M Lee 12, Gerard Lozanski 11, Maciej Pietrzak 11, Michal Seweryn 11,13,14, Woo Yul Byun 11, Katja Schulze 15, Alan Nicholas 15, Ann Johnson 15, Jessica Grindheim 15, Stephanie Hilz 15, David S Shames 15, Chris Rivard 7, Eric Toloza 16, Eric B Haura 16, Ciaran J McNamee 9,10, G Alexander Patterson 17, Saiama N Waqar 17, Valerie W Rusch 1, David P Carbone 3,18,✉; LCMC study investigators
PMCID: PMC10803254  PMID: 37816821

Correction to: Nature Medicine 10.1038/s41591-022-01962-5. Published online 12 September 2022.

In the version of this article initially published, the first sentence of the Fig. 4a caption (now reading “The expression of different NK cell surface receptors was determined by scRNA-seq”) was incorrectly preceded by the text “Association between gene expression in NK cells and the percentage of viable tumor cells,” which has now been removed from the HTML and PDF versions of the article.

Contributor Information

David P. Carbone, Email: david.carbone@osumc.edu

LCMC study investigators:

Saiama N. Waqar, Elaine Shum, Misako Nagasaka, Marianna Koczywas, Edward B. Garon, David J. Finley, David R. Camidge, Jennifer W. Carlisle, and Justin D. Blasberg

Articles from Nature Medicine are provided here courtesy of Nature Publishing Group

RESOURCES